UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM	8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2019

PIERIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation) 255 State Street, 9th Floor Boston, MA (Address of principal executive offices)

Common Stock, \$0.001 par value per share

001-37471

30-0784346 (IRS Employer Identification No.) 02109

(Zip Code)

The Nasdaq Capital Market

Registrant's telephone number, including area code: 857-246-8998

(Former name or former address, if changed since last report.)

	Title of each class	Trading Symbol(s)	Name of each exchange on which registered		
Securities regi	stered pursuant to Section 12(b) of the Act:				
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 2	40.13e-4(c))			
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)				

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

PIRS

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 8.01: Other Events.

On September 26, 2019, the European Respiratory Society published Pieris Pharmaceutical, Inc.'s (the "Company's") poster related to its phase 1 multiple ascending dose study of PRS-060, entitled Multiple ascending dose study of an inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma. The poster is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 PRS-060 Multiple Ascending Dose Study Poster.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PIERIS PHARMACEUTICALS, INC.

Dated: September 26, 2019

/s/ Tom Bures
Tom Bures

VP Finance

Ast


Multiple ascending dose study of the inhaled IL-4Rα antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma


Bruns IB,¹ Fitzgerald MF,¹ Mensing G,¹ Tsung M,¹ Pardali K,² Gardiner P,³ Keeling DJ,² Axelsson LT,² Olsson M,⁴ Ghobadi C,² Walsh O,⁵ McLendon K,⁶ Farinola N,† Hatchuel L,⁶ Close DR²

*Pieris Pharmaceuticals, Boston, MA, USA; *Early Respiratory, Inflammation and Autoimmunity, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; *Data Science and Al, BioPharmaceuticals R&D, AstraZeneca, Got

lable 1. Baseline oberacterist	es-		
Parameter	Placeto (N = 12)	AZD14(0)PR8-000 (N = 93)	Dverall (N = 42)
Age, years, mean (range)	28.8 (19-62)	284 (19-51)	35.A (19-52)
Sex. Pale. F	11	34	MF.
Haco, n			
With		25	35
Asian Partic Islandor			6
Other	2	2	-4
BM. kg/y/, enun burgst	27.7 (22.5-34.8)	28.0 (20.5-33.4)	25.7 (29.5-34.6)
PeNO, ppt at pre-obes day 1, mean (range)	81.2 (28-122)	81.7 (32-179)	75.9 (28-178)
FEV, ms. at pre-door day %. Yearn Dangel	3730 8 (3560-4770)	3901.7 (2090-9370)	2652.9 (2545-507)
FEV. FUCKER IS A FIRST	74 7 (63-89)	74.9 (03.97)	24.1-92-90







1 2 3 4 5 4 Titree () domining the billion of the process domining the sold constitution is princed assets.	 The significant and pronounce there is minimal systemic targ drug is sufficient to reduce air The onnet of FeHO reduction versus placels was sustained 				
Mean steady-state exposures.			Systemic target engagement (with systemic expessive of the		
02/PRS-000 delivered dose bold, reg	AUCycou Kinstell	C. rightl.	PK exposure data demonstrat		
	ND AD	AD.	day 10 exposure was consiste		
	54 (14)	63(1.6)	 Pulmorary target engagement 		
	210 (98)	28 (18)	profile of AZD1402/PRS-090, of inhaled therapy for authora.		
	780 (340)	101 (01)	and the same of the same of		
eer (M.); one under the comment other have come from the 12 house. of deposition.	and total date Co., respectively	star, NE), or presented.	References		

to consent other has come from the 12 february bond, below dath, Co., recommunication, MC, and dehanment. Ideal reliabling percentage reduction in FeMO.				References	
cec h.i.d. mg	·#.	LS mean reduction vs. baseline, % (95% GE	Mediation vs placebo.	D. AMORA.	Acknowledgements
	- 6.	43.8 (21-64)	24.0 (1.8-41)	104	The shirty may operate sortly their Phormacourism and states in AutoConcre Marked of their
	20	44.1 (21-54)	34.3 (2.7-41)	0.00	Shall family (MI) of Pramabanes Lindon, Contin. LM. The Samos small but the related and
	112	53.1 (48-59)	36.4 (22-48)	< 0.0001	Author disclosures
	W.	48.7 (37-68)	30.5 (15-0))	0.005	With an extract and destroyed Peris Premions state, MT is a consider and phenomial
	12	26.2 (14-36)			anables of Pers Promosomer. After an anables of Pers Promose area. 4775, 531, 531, 531, 531, 531, 531, 531, 53
					greatures of Different Pro Link Hendrin, Australia, Mills an amongs of UMAX Chang Research Po